Spero Therapeutics Inc
SPRO
Market Cap$70.26M
Close$
$5.29
87.1% upside
Current Fair Value
87.1% upsideUndervalued by 87.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $70.26 Million |
|---|---|
| Enterprise Value | $44.68 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $0.43 |
| Beta | 0.62 |
| Outstanding Shares | 53,957,766 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 4.02 |
|---|---|
| PEG | -4.02 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.29 |
| Enterprise Value to EBIT | -0.58 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.52 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Spero Therapeutics Inc
89 employees
CEO: Ankit Mahadevia Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.